Skip to content

Study · Not a test of the peptide alone · 1999

1 result

Dimerization of profilin II upon binding the (GP5)3 peptide from VASP overcomes the inhibition of actin nucleation by profilin II and thymosin beta4.

Jonckheere V, Lambrechts A, Vandekerckhove J, Ampe C

FEBS letters1 Mar 1999Cited by 37 (Europe PMC)

PMID10214957 (opens in a new tab)DOI10.1016/s0014-5793(99)00293-8 (opens in a new tab)PepBankPUB-10214957
Source linkPubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone1

In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymosin beta-4 (human).

  1. 01LabNot a test of Thymosin beta-4 (human) aloneIn vitro (cell-free)Mechanism

    In a cell-free actin assay, the profilin II-VASP (GP5)3 peptide complex overcame the combined inhibition of actin nucleation by thymosin beta4 and profilin II and restored filament formation.

    In plain wordsIn lab tests, a profilin II-peptide complex reversed the block of actin filament formation caused by thymosin beta4 and profilin II together.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    IncreaseActin nucleation and filament formation with Tβ4 and profilin II plus VASP peptide
    Study

    n: not reported in source

    actin nucleation assay
    Outcome group
    Receptor activity and mechanism · Pharmacology

    Source sentences

    Summary
    The resulting profilin II-peptide complex overcomes the combined capacity of thymosin beta4 and profilin II to inhibit actin nucleation and restores the extent of filament formation.

    In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 01:52 UTC

    Study results updated

  2. Version 1

    12 Oct 2026, 18:17 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.